Format

Send to

Choose Destination
Rheum Dis Clin North Am. 2014 Aug;40(3):497-506, viii. doi: 10.1016/j.rdc.2014.04.005. Epub 2014 Jun 3.

Systemic lupus erythematosus and malignancies: a review article.

Author information

1
Division of Clinical Epidemiology, McGill University Health Centre, 687 Pine Avenue, V Building, Montreal, Quebec H3A 1A1, Canada.
2
Division of Rheumatology, University of Calgary, 3330 Hospital Drive Northwest, Calgary, Alberta T2N 4N1, Canada.
3
Division of Rheumatology, Northwestern University Feinberg School of Medicine, McGaw Pavilion, 240 East Huron Street, Suite M-300, Chicago, IL 60611, USA.
4
Division of Rheumatology, College of Medical and Dental Sciences, University of Birmingham, Edgbaston B15 2TT, UK.
5
Department of Therapeutic Radiology, Yale School of Medicine, 333 Cedar Street, New Haven, CT 06520, USA.
6
Division of Clinical Epidemiology, McGill University Health Centre, 687 Pine Avenue, V Building, Montreal, Quebec H3A 1A1, Canada. Electronic address: sasha.bernatsky@mcgill.ca.

Abstract

The systemic lupus erythematosus (SLE) population has a unique cancer risk profile. This article presents the most recent data on risk of cancer in lupus and discusses possible contributing factors. The risk of lymphoma is particularly increased in SLE and may be mediated by immunosuppressive medication. Lung cancer risk is also increased in SLE. There is a high rate of cervical dysplasia in women with SLE. A similar pathophysiology could be responsible for the trend seen in vulvovaginal and hepatic carcinomas. There is a decreased risk in SLE for some hormone-sensitive cancers, but the cause of this remains unclear.

KEYWORDS:

Cancer; Epidemiology; Malignancy; Systemic lupus erythematosus

PMID:
25034158
DOI:
10.1016/j.rdc.2014.04.005
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center